Sanofi India Shareholders Approve Deepak Arora's Appointment as Managing Director

Sanofi India Limited has successfully concluded its postal ballot process, with shareholders overwhelmingly approving the appointment of Deepak Arora as Director and Managing Director of the company. The voting results, announced on December 18, 2025, show strong shareholder confidence in the proposed leadership change.

Voting Results and Approval

The postal ballot concluded with decisive approval for both resolutions:

Resolution	Votes in Favour	Votes Against	Approval Rate
Director Appointment	1,99,46,099	31,256	99.84%
Managing Director Appointment	1,89,18,505	10,58,858	94.70%

The e-voting process, conducted through NSDL's platform, saw participation from 23,03,062 shareholders representing 86.74% of the total voting rights.

Appointment Details

With shareholder approval secured, Mr. Deepak Arora's appointment is now confirmed for a three-year term from October 27, 2025, to October 26, 2028. The 52-year-old executive brings over 30 years of pharmaceutical industry experience to his new role.

Parameter	Details
Position	Director and Managing Director
Term Duration	3 years (Oct 27, 2025 - Oct 26, 2028)
DIN Number	07495638
Industry Experience	30+ years in pharmaceuticals

Remuneration Structure

The approved remuneration package for Mr. Arora includes:

Component	Annual Amount
Basic Salary	₹1,36,25,000
Flexi Compensation Plan	₹1,13,34,638
Performance Bonus (Target)	₹68,12,500

Additional benefits encompass provident fund, gratuity, increments, relocation support, leave travel allowance, insurance coverage, and other perquisites as per company policy.

Voting Process and Timeline

The postal ballot process was conducted entirely through electronic voting:

Notice Circulation: November 17, 2025
E-voting Period: November 18, 2025 (9:00 AM) to December 17, 2025 (5:00 PM)
Results Declaration: December 18, 2025
Cut-off Date: November 14, 2025

Mr. Gaurav Sainani from SGGS Associates served as the scrutinizer for the voting process, ensuring transparency and compliance with regulatory requirements.

Professional Background and Regulatory Approval

Mr. Arora holds a Bachelor's degree in Botany & Zoology from the University of Lucknow and an MBA from Indira Gandhi National Open University. His extensive experience spans sales and marketing leadership, brand development, product management, and business acquisition across local and international markets including the US, Europe, Japan, Africa, and the Middle East.

The appointment requires Central Government approval as Mr. Arora has not been residing in India for the required 12 months prior to the appointment date, in accordance with Schedule V of the Companies Act, 2013.

The successful approval of both resolutions demonstrates strong shareholder confidence in the Board's recommendation and Mr. Arora's capabilities to lead Sanofi India through its next phase of growth in the Indian pharmaceutical market.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.32%	+0.17%	-3.89%	-31.71%	-31.93%	-49.98%

Sanofi India Limited , a prominent player in the pharmaceutical sector, has released its financial results for the third quarter ended September 30. The company demonstrated mixed performance, with improved profitability margins despite a decline in revenue and net profit.

Financial Highlights

Metric	Q3 (Current Year)	Q3 (Previous Year)	Change
Revenue	₹475.40 crore	₹524.00 crore	-9.30%
EBITDA	₹134.00 crore	₹120.00 crore	+11.67%
EBITDA Margin	28.00%	23.00%	+5.00 percentage points
Net Profit	₹76.00 crore	₹82.00 crore	-7.32%

Key Takeaways

Revenue Decline: Sanofi India experienced a year-over-year decrease in revenue from ₹524.00 crore to ₹475.40 crore, representing a decline of 9.30%.
Improved EBITDA: Despite the revenue drop, the company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased from ₹120.00 crore to ₹134.00 crore, showing a growth of 11.67%.
EBITDA Margin Expansion: The EBITDA margin saw a significant improvement, rising from 23.00% to 28.00%, indicating enhanced operational efficiency.
Net Profit Decrease: The company's net profit declined from ₹82.00 crore to ₹76.00 crore, a decrease of 7.32% compared to the same quarter last year.

Corporate Actions and Strategy

Interim Dividend: The Board declared an interim dividend of ₹75 per equity share. The record date for this dividend is set for November 7.
Portfolio Streamlining: Sanofi India is focusing on streamlining its portfolio to concentrate on core therapeutic areas, including diabetes and cardiovascular treatments.
Cost Efficiency: The company's improved EBITDA and operating margin are attributed to cost efficiency measures and a favorable product mix.

Market Performance

Following the results announcement, Sanofi India's shares remained largely unchanged at ₹4,747.00. The stock has gained 22% year-to-date, indicating overall positive investor sentiment despite the mixed quarterly results.

The mixed results reflect the challenging environment in which Sanofi India operates. While the company has managed to improve its operational efficiency, as evidenced by the higher EBITDA and margin, the decline in revenue and net profit indicates ongoing market pressures.

Investors and stakeholders will likely be watching closely to see how Sanofi India's strategic moves, such as portfolio streamlining and cost efficiency measures, will impact its performance in the coming quarters. The company's ability to maintain its improved margins while addressing the revenue decline will be crucial for its future financial health.